General Information of Drug (ID: DM4VZCW)

Drug Name
Polyinosinic:polycytidylic acid Drug Info
Synonyms
NSC-120,949; PI:C; Poly 1-poly-c; Poly C poly I; Poly I:poly C; Poly IC; Poly rI:poly rC; Poly(I).poly(C); Poly(I).poly(C) complex; Poly(I:C); Poly(rI)-poly(rC); Poly(rI).(rC); Poly(rI).poly(rC); Poly(rI:rC); Polycytid; Polyinosinic acid.polycytidylic acid; Polyinosinic-polycyticylic acid complex; Polyriboinosinic acid:polyribocytidylic acid; polyinosine-polycytosine
Indication
Disease Entry ICD 11 Status REF
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [1]
Therapeutic Class
Antiviral Agents
Cross-matching ID
PubChem CID
135618150
TTD Drug ID
DM4VZCW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Drug Name Drug ID Indication ICD 11 Highest Status REF
Rintatolimod DMSDZ8U Chronic fatigue syndrome 8E49 Phase 1/2 Trial [2]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HUMAN toll-like receptor 3 (TLR3) TT1CN09 TLR3_HUMAN Agonist [1]

References

1 Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development. J Immunol Res. 2019 Apr 7;2019:6491738. doi: 10.1155/2019/6491738.
2 Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Expert Rev Clin Pharmacol. 2016 Jun;9(6):755-70.